Introduction
Cells selected for resistance to a single cytostatic drug may become cross-resistant to a wide spectrum of drugs that do not share a com mon structure or target. This kind of drug resistance is known as multidrug resistance. The classical form of MDR1 in human cells is due to increased activity of the P-glycoprotein encoded by the MDRI gene (for a review see Ref. l ) . This large glycoprotein is located in the cell membrane and is thought to lower the intracellular concentration of cytotoxic drugs by active extrusion of these drugs from the cell. In addition to P-glycoprotein-mediated MDR, at least two other types of MDR have been described, an "atypical" MDR due to alterations in the level or drug sensitivity of Topolla (2) and a "true" form of non-Pgp mediated MDR (3) (4) (5) . In a recent paper, Cole et al. (6) reported that this non-Pgp mediated MDR was associated with the overexpression of a novel gene, called MRP for A/DR-flelated Protein, in both of the cell lines examined. This gene is thought to encode a protein of 1522 amino acids belonging to the ATP-binding cassette (ABC) superfamily of membrane proteins to which the MDRI Pgp also belongs (1, 6) . This suggests that MRP is a transporter that may confer or at least contribute to MDR in SCLC and in other malignan cies as well (6) .
In previous work we have characterized a set of human lung cancer cell lines resistant to MDR drugs. Some of these were derived from the non-SCLC line SW-1573; another one was from the SCLC line GLC4 (7-10).4 These lines display a non-Pgp MDR phenotype in addition to other alterations (5, 10).5 Using a sensitive RNase protec tion assay we examined whether overexpression of MRP can account for non-Pgp MDR in these lines.
Materials and Methods
Cell Lines. S l is a subline of the human non-small cell lung cancer cell line SW-1573. The non-Pgp MDR cell lines 1R50Ã'and 2R50 were isolated from SI by a multistep selection up to 50 nMdoxorubicin (7, 8) . The non-Pgp MDR cell line 2R120 and the Pgp MDR cell line 2R160 were obtained after stepwise further selection of 2R50 on, respectively, 120 and 160 nM doxorubicin (9). 5R30 is a subline of SI that is resistant to doxorubicin, but not to vincristine, and that was isolated by a single step at 30 HMdoxorubicin.4 30.3, 30.10, 30.14, 30.31, 40.3, 40.10 and 40.12 are non-Pgp MDR cell lines, that were isolated from Slow, a subclone of SI (5), by a single step selection at 30 nM (30.x series) or 40 nM (40.x series) doxorubicin.4 GLC4 is a human small cell lung cancer cell line derived from a pleural effusion. The non-Pgp MDR cell line GLC4/ADR was isolated from GLC4 by a multistep selection up to 1152 nM doxorubicin (10).
Cloning of MRP cDNA. By PCR amplification of cDNA from IRSOb cells,5 two fragments corresponding to nucleotides 240-484, and nucleotides 4420â€"4657of the MRP mRNA sequence were isolated (II). The fragment from 240-484 overlaps with codons 6-87 of the deduced amino acid sequence of the MRP gene; the 4420-4657 fragment overlaps with codons 1331-1410 of the amino acid sequence. The primers used for amplification of the 240-484 fragment were 5'-GGGAATTCTGGGACTGGAATGTCACG-3' (forward primer) and 5'-CGGGATCCAGGAATATGCCCCGACTTC-3:
(reverse prim er); for the 4420-4657 fragment they were 5'-GGGAATTCTGAAGGACT-TCGTGTCAGCC-3' (forward) and 5'-CGGGATCCCGTCCATGATGGTGT-TGAGCC-3' (reverse). In all primers the first eight nucleotides are not complementary to the MRP mRNA. In the forward primers these eight nucle otides serve to generate an EcoRl site at the 5'-end of the amplified fragments; in the reverse primers these nucleotides serve to generate a Bam\\\ site at the 3' end of the fragments. The amplified fragments were digested with BamH\ and Â£coRI and inserted into the plasmid vector pGEM3-Zf(-) (Promega, Madison, WI). The DNA sequences of the cloned DNAs were determined and found to be identical to the published sequences (GenBank accession number MRP cDNA: L05628) (6). PCR amplification of genomic DNA using the two primer sets gave fragments of 400 base pairs (240/484 primers) and 1.6 kilobases (4420/4657 primers), indicating that both encompass introns. This excludes that the products obtained in the RNase protection experiments are caused by hybridization to DNA.
RNA. Cytoplasmic RNA from cell lines was isolated by a Nonidet P-40 lysis procedure (12). Total cellular RNA from tissue samples obtained during surgery or at autopsy was isolated by acid guanidinium isothiocyanate-phenolchloroform extraction (13). 
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1ND 25 " Relative resistance (IC50 cell line/IC50 parent) was determined in growth inhibition assays (IC50 = inhibitory concentration where 50% of the cells survive). Data are from Refs. 4, 7-9. and 20.
* Relative expression of Topolla, MDR1, and MRP genes were determined by RNase protection (data from Refs. 4,5,9, and 21 and this paper), except for the expression of the Topolla gene in GLC4/ADR and 2R120 which were measured by an enzymatic assay (20, 22) . ND, not detectable; NM, not measured.
RNase Protection. a-12P-Labeled RNA transcripts complementary to MRP mRNA sequences were transcribed from Â£coRI-linearized DNA from PMRP-5' or pMRP-3' using SP6 RNA polymerase. RNase protection was carried out as described (4, 14) . Protected probe was visualized by electrophoresis through a denaturing 6% acrylamide gel, followed by autoradiography. In all experiments a probe for -y-actin was included as control for RNA recovery (4, 5). The amount of MRP mRNA relative to the amount of y-actin mRNA was calculated from densitometric scanning of autoradiograms. The signals on the autoradiograms were proportional to the input RNA, as was verified by adding different amounts of total RNA to the reactions. DNA Analysis. Isolation of genomic DNA, agarose gel electrophoresis, and DNA (Southern) blot analysis followed standard procedures (12).
Results
To determine the level of MRP mRNA in our cell lines we used a RNase protection method used previously to accurately determine the amounts of MDR1 and Topolla. mRNA in cell lines (4, 5) . This method is quantitative, sensitive, and rather invulnerable to partial RNA degradation, not a trivial concern inasmuch as MRP mRNA was estimated to be around 8 kilobases (6). Two segments of the MRP gene were chosen for amplification by PCR and cloned behind a promoter for the SP6 RNA polymerase, as described in "Materials and Methods." Radioactive RNA copies of the linearized recombinant plasmid were obtained by transcription with SP6 RNA polymerase in vitro and these were used for RNase protection experiments. The two DNA segments used in these experiments were chosen from domains of the MRP cDNA that are known to contain some sequences that are relatively poorly conserved among the ABC family of transporter proteins. Both segments gave similar quantitative results, confirming that our assay only looks at MRP mRNA.
The expression of MRP mRNA was analyzed in 12 resistant sublines of SW-1573 and one resistant subline of GLC4 (Table 1) . Some of these lines have been described in detail before (4, 5, 7-10). The 30.x and 40.x series are non-Pgp MDR cell lines recently isolated from SW-1573 by Eijdems et al.4 5R30 is a SW-1573 subline that is resistant to doxorubicin but not to vincristine.4
Representative RNase protection experiments are shown in Fig. 1 . To normalize for RNA input, we analyzed each RNA preparation also for 7-actin mRNA. There were no major qualitative differences bea o. tween the MRP mRNA levels of the SW-1573 non-Pgp cell lines and the parental cell line from which they are derived ( Fig. 1; Table 1 ). The RNA levels were quantitated by scanning of suitable autoradiograms. In all SW-1573 derived cell lines the MRP mRNA level rela tive to -y-actin mRNA was equal to that in the parental line within 35%. We conclude that non-Pgp mediated MDR is not associated with increased levels of MRP mRNA in the drug resistant cell lines derived from the human non-SCLC SW-1573 line.
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In contrast, the non-Pgp MDR line GLC4/ADR derived from the SCLC line GLC4 displays a massive increase in MRP mRNA relative to the parental cell line, estimated by densitometry to be 25-fold ( Fig.   1 ; Table 1 ). This increase is accompanied by an increase in the MRP gene copy number (Fig. 2) . We estimate the increase in MRP gene copy number to be similar to the increase in MRP mRNA in GLC4/ ADR, i.e., about 25-fold. Zijlstra et al. (IO) have reported that the GLC4 parental line con tains about 40 double minute chromosomes per cell and that this number had doubled in the GLC4/ADR line. This 2-fold increase does not correspond to the 25-fold increase in MRP gene copy number. It is possible, however, that the additional double minute chromosomes 
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â€"¿ â€¢¿ â€"¿ i act in 72-â€"¿ in GLC4/ADR are unrelated to those already present in GLC4. Ex periments are in progress to test this possibility. Cole eÂ¡ al. (6) reported that MRP mRNA is detectable in Northern blots of total RNA from lung, testis, and peripheral blood mononuclear cells but not from placenta, brain, kidney, salivary gland, uterus, liver, and spleen (6). Using RNase protection, however, we readily detected substantial amounts of MRP RNA in all tissues analyzed (Fig. 3) , including some of the tissues found negative by Cole et al. (6) . The difference may be due to the difficulty of obtaining human RNA samples in which mRNAs as large as 8 kilobases are still intact. Further work is required to determine whether MRP expression is limited to specialized cells within these tissues, such as connective tissue, or ubiquitous. Nevertheless, it is useful to know at this stage that MRP should be represented in available cDNA libraries known to contain full-length cDNAs of lung mRNAs. This should simplify the isolation of MRP cDNA suitable for transfection experiments.
Discussion
The simplest interpretation of our results is that overexpression of the MRP gene plays a role in non-Pgp MDR in the two cell lines described by Cole et al. (6) and in the GLC4/ADR cell line analyzed here, but not in the MDR lines derived from the non-SCLC SW-1573 line. Two other interpretations should be considered, however. First, it is possible that increased activity of the MRP protein is also respon sible for the drug resistance of the SW-1573 derived non-Pgp cell lines but that this is not reflected in an increased level of the MRP mRNA. The mRNA might be more efficiently translated, or the protein might be more stable or modified to increase its catalytic activity. The second possibility is that MRP overexpression is involved in multidrug resistance neither in the SW-1573 derived cell lines nor in the lines in which it is overexpressed. This alternative is not as far fetched as it may seem. The MRP protein admittedly resembles an ABC-type transporter protein, but, as already stressed by Cole et al. MRP is a rather distant relative of the P-glycoproteins known to transport hydrophobic cationic drugs such as the P-glycoprotein encoded by the human MDR\ gene. MRP is in fact most related to the ABC-trans porter encoded by the pgp\ gene of Leishmania larentolae (15). This Leishmania protein is now known to be involved in low level oxyanion (arsenite) resistance, rather than resistance to hydrophobic drugs (15, 16) . It is therefore not obvious that overproduction of MRP could give rise to a typical mammalian form of multidrug resistance. It is also unclear how overproduction of an ABC-transporter could cause resistance in Cole's H69AR line that does not appear to have a lowered drug accumulation. Cole et al. (6) speculate "that sequestra tion of drugs in these resistant cells may be modified so that drugs are less able to reach their intracellular site of action." However, such redistribution cannot result in lowered drug concentration at target in the steady state unless there is increased drug export from the cell (cf. Ref. 1). This increase has not been found in the H69AR line (17).
We also note that the increase in the MRP mRNA level in the two resistant cell lines studied by Cole et al. and in the GLC4/ADR studied by us is exactly paralleled by an increase in the copy number of the MRP gene (6). This is somewhat unusual for drug resistance genes in human cells, where transcriptional activation usually accom panies gene amplification, if amplification is present at all (1, 18). It is therefore possible that the overexpression of the MRP gene in three MDR cell lines is due to coamplification of the MRP gene as part of an amplicon containing the real gene responsible for multidrug resis tance in these cell lines, a possibility already mentioned by Cole et al. (6) . This would be analogous to coamplification of the mdr2lpgp3 genes and the sorcin gene in many rodent cell lines in which resistance is due to amplification of genes for drug transporting P-glycoproteins (18, 19).
To test these alternatives, it will be necessary to determine whether overexpression of the MRP gene results in multidrug resistance in transfected cells or whether suppression of MRP expression reverses resistance. Such experiments are in progress.
